Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Project Oncology®
CAR T-Cell Therapy in R/R LBCL: Overcoming Barriers to Referral and Completion
Alexandria May, PharmD, BCPS; Tara Graff, DO, MS
- Alexandria May, PharmD, BCPS
- Tara Graff, DO, MS
Making the Most of Biomarker Testing in NSCLC
Making the Most of Biomarker Testing in NSCLC
On the Frontlines of Non-Small Cell Lung Cancer
Making the Most of Biomarker Testing in NSCLC
Steve Jackson, PharmD; Angel Qin, MD
- Steve Jackson, PharmD
- Angel Qin, MD
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
MinuteCE®
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
MinuteCE®
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
MinuteCE®
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
0.75 program credits
- Gerard A. Silvestri MD, MS
0.75 program credits
Biomarker Testing After Progression in HR+/HER2- mBC
Biomarker Testing After Progression in HR+/HER2- mBC
On the Frontlines of Metastatic Breast Cancer
Biomarker Testing After Progression in HR+/HER2- mBC
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Project Oncology®
Interpreting Oral SERD Trial Data to Guide Metastatic Breast Cancer Care
Alexandria May, PharmD, BCPS; Neil M. Iyengar, MD
- Alexandria May, PharmD, BCPS
- Neil M. Iyengar, MD
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
On the Frontlines of Metastatic Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS; Heather McArthur, MD, MPH, FASCO
- Alexandria May, PharmD, BCPS
- Heather McArthur, MD, MPH, FASCO

Medical News

Medical News
DCIS Surgery: Survival Associations in Women 70 and Older
11/10/2026
Read more
Medical News
Timely ED Pain Care Linked to Relief in Terminal Cancer Cohort
11/09/2026
Read more
Medical News
Shoulder Desmoid Tumors: More Symptoms, No EFS Site Difference
11/09/2026
Read more
Medical News
HIFU for Abdominal Wall Desmoid Tumors: Response and PFS
11/09/2026
Read more

CME/CE

The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
MinuteCE®
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
KRAS G12C Biology: Why Is This Mutation Different?
KRAS G12C Biology: Why Is This Mutation Different?
MinuteCE®
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
MinuteCE®
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits

Clinical Practice

Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
MinuteCE®
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
CME/CE
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
0.50 credits
- Jennifer R. Brown, MD, PhD
0.50 credits
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Clinician's Roundtable
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Nicholas Pastis, MD
- Nicholas Pastis, MD
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP

Programs

Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC
Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC
On the Frontlines of Non-Small Cell Lung Cancer
Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC
Steve Jackson, PharmD; David Carbone, MD, PhD
- Steve Jackson, PharmD
- David Carbone, MD, PhD
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
CME/CE
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
Amer Zeidan, MBBS; Guillermo Garcia-Manero, MD
0.50 credits
- Amer Zeidan, MBBS
- Guillermo Garcia-Manero, MD
0.50 credits
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
Solange Peters, MD, PhD
0.50 credits
- Solange Peters, MD, PhD
0.50 credits
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS